"Mannkind Corporation (NASDAQ:MNKD): Those that have followed the up-and-down year of trading for shares of Mannkind largely expected that a late-year round of financing would unfold as the company looked to fund the remained of Afrezza’s development to market as a potential inhaled insulin alternative to the needle for diabetics. The news finally came last week as MNKD shares plunged to below the two dollar mark when it was revealed that the public offering consisted of 40 million shares and 30 million warrants to buy another 0.75 share, all priced at $2.00. In conjunction with the financing, CEO Al Mann relieved the company of over two hundred million in debt in return for more shares. This deal will fill Mannkind’s coffers with $80 million and allow for the final stages of Afrezza development before the product again goes before the FDA. Dilution was massive — again — for shareholders who held through the recent turmoil and the offering, but last week’s dip — that will likely carry into the new trading week — could again attract investors willing to take a position on the potential of Afrezza. Data from the last Phase III trial was encouraging, although the trial was not conducted with the same inhaler that the company planned to market. The latest trials will test Afrezza with the next-generation inhaler. With financing out of the way and given the sharp drop in share price last week, MNKD will be one to watch this week."

http://marketplayground.com/2012/10/21/weekly-stock-watch-goog-msft-ibm-intc-mcd-yum-aapl-amrn-sgyp-clsp-irwd-frx-nbs-actc-gern-ssh-htwr-thor-mnkd-dndn-aet-oncs-siri-lmca-jpm/